In 2018, 866000 people developed TB and 37000 died of TB (these two numbers are 10 times the number of confirmed and dead coronavirus diseases in 2019). The situation calls for no delay. In China, a special case of TB development is that as many as 66000 patients are estimated to be resistant to first-line treatment drugs, accounting for 13.6% of the global MDR / rifampicin resistant TB cases. In 2018, less than a quarter of MDR-TB patients (15000 people) were diagnosed, of which only 60% (9000) received second-line treatment, with a success rate of only 52%.